Schedule a Meeting
Get a SampleSeptember 2023
The global precision medicine market size is calculated at USD 119.03 billion in 2025 and is predicted to reach around USD 470.53 billion by 2034, accelerating at a CAGR of 16.50% from 2025 to 2034. The North America precision medicine market size surpassed USD 55.17 billion in 2024 and is expanding at a CAGR of 16.52% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global precision medicine market size was estimated at USD 102.17 billion in 2024 and is predicted to increase from USD 119.03 billion in 2025 to approximately USD 470.53 billion by 2034, expanding at a CAGR of 16.50% from 2025 to 2034.
The U.S. precision medicine market size was estimated at USD 49.79 billion in 2024 and is predicted to surpass USD 232.49 billion by 2034, at a CAGR of 16.66% from 2025 to 2034.
In terms of revenue, North America captured the largest share of the market in 2024 and is projected to maintain its dominance in the coming years. The market growth in the region is primarily attributed to the increasing prevalence of cancer and the rising approval of personalized medicines. The demand for precision medicine in North America is mainly driven by favorable government initiatives and rising investments for developing novel solutions for effective disease management.
The market in Asia Pacific is anticipated to expand at the fastest growth rate during forecast period due to the increasing disease burden. The rising disposable income and rising economy in the developing nations such as India and China expected to boost the demand for precision medicines in the region. The region offers several aspect of growth in the medical sector owing to on-going research and significant investment on health care facilities and techniques. Furthermore, increasing government initiatives to increase health awareness boosts the market. For instance,
Precision medicine, also known as personalized medicine, is an innovative healthcare approach to disease treatment that tailored treatments and interventions according to the individual characteristics such as lifestyle, genetics, and environment. This personalized approach has the potential to revolutionize healthcare and enhance treatment efficacy, thereby improving patient outcomes. The market witnessed significant growth over the years due to rising demand for personalized healthcare saolutions. Moreover, the market is expected to expand rapidly during the forecast period owing to the increasing advancements in genomics and the rising instances of chronic conditions. Precision medicine leads to effective chronic disease management, improving patient quality of life. For instance,
Advancements in Genomics and Rising Investments for Developing Novel Therapies
Precision medicine analyzes the genes and proteins present in the patient’ body to accordingly design the personalized treatment to cure the particular disease. With key discoveries such as single nucleotide polymorphism and microarray/biochips in the field of precision medicine, the market expected to experience a boom in the coming years. Research on human genome is the future of precision medicine and has significant potential to upend the medical treatment on individual patients by understanding their genetics, molecular profiles, and clinical characteristics and evolving proper treatment to cure the disease. The aforementioned factors projected to flourish the demand for precision medicine in the near future. Moreover, the rising prevalence of cancer is expected to boost the demand for precision medicine for personalized therapeutics and diagnostics, which boost the market growth. For instance,
Advancements in genomics have transformed clinical diagnosis & personalized medicine. Advancements such as next-generation sequencing (NGS) and high-density microarray allow for rapid analysis of extensive genomic data, enabling quick exploration of disease genetics. NGS is effective in identifying disease-causing variations, facilitating early detection of genetic disorders accurately. Additionally, the rising investments in human genome for developing targeted therapies are anticipated to drive the market in the coming years. For instance, human genome funding by the National Institutes for Health (NIH) was about US$ five million in fiscal year 2023 and is expected to increase in the coming years. Funding helps companies to generate genomic data from bio-samples that is a critical component of precision medicine discoveries.
| Report Coverage | Details |
| Market Size in 2024 | USD 102.17 Billion |
| Market Size in 2025 | USD 119.03 Billion |
| Market Size by 2034 | USD 470.53 Billion |
| Growth Rate from 2025 to 2034 | CAGR of 16.50% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Technology, Application, End User, Sequencing Technology, Product, Route of Administration, Drugs, Region |
| Regions Covered | North America, Asia Pacific, Europe, Latin America, Middle East and Africa |
High Cost and Lack of Reimbursement Policies
High cost of precision medicine along with challenges in reimbursement policies are expected to hinder the market growth. The application of high-end calculation methodology and advanced computational techniques add various types of cost to the treatment procedure, making precision medicine expensive. Apart from this, on-going advancement in the computational tools and innovation in the genetic technology helps to examine the functional effects of genetic changes that finally cause cancer development. Thus, genetic diagnosis approach predicted to fuel the growth of precision medicine exponentially especially in the field of cancer treatment.
Targeted Gene Therapy
The gene therapy creates immense opportunities for companies engage in precision medicine. Since genome sequencing is an unavoidable phase of gene therapy, the substantial investments that are being made in this field would propel the growth of the precision medicine market. Globally, rising cancer prevalence is likely to increase the demand for gene therapy as an effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach more than 20 million by the end of this decade. This alarming increase in the number of patients necessitates gene therapy as a potential treatment approach addressing the growing global burden of the disease.
As the number of gene therapy clinical trials reporting positive results increases, it is becoming clear that the gene therapy is moving toward commercialization. Being a part of the portfolio mixes for many of the biggest companies in the biopharmaceutical arena, gene therapy is suddenly a hot investment sector. Spark Therapeutics (ONCE) and GlaxoSmithKline (GSK) priced the world's first approved gene therapies at figures approaching $1.0 million apiece. Spark's Luxturna treats a rare eye disease that causes blindness. Glaxo's drug, Strimvelis, is approved in Europe to treat an immunodeficiency disease, often referred to as "bubble-boy disease" in children. It costs about $714,000.
Expansion into the Emerging Markets
Most of the companies providing precision medicine solutions have limited their operations to the developed markets, leaving the immense potential of the emerging markets untapped. The countries, such as China, India, Australia, and countries of the Middle East and Africa, possess population with a high risk of diseases (whose treatment requires gene sequencing) in high numbers and offer a great opportunity for the expansion of the precision medicine market.
Although the field of genetics and genomics are well-established in developed countries, significant progress has also been made by the developing countries for genetics and precision medicine in the past ten years, in terms of regulations, product approvals, and implementation of novel methods and procedures in healthcare. A critical issue faced by the emerging countries is the reimbursement of genetic testing by the health insurance companies. In the recent years, healthcare insurance companies that are recognized in the developing economies are agreeing to cover the costs of genetic diagnostic testing of their clients, and thus offer this new technology to patients and their at-risk relatives.
Funding programs by the public healthcare systems in the emerging countries are probably based initially on searching for mendelian germline genetic mutations, such as those occurring in cancer genetics. This increases the affordability and accessibility of screening for mendelian diseases among the population of the developing economies. In addition, funding by the private healthcare systems play a major role in supporting small innovative players in the emerging regions that are focused on new and informative genetic tests.
Proper regulation of guidelines and policies for genetic testing is another factor supporting the growth of precision medicine in emerging economies. For instance, proper and easy approval of the Genetic Information Nondiscrimination Act (GINA) law by many developing countries helped to prohibit genetic discrimination in health insurance and also genetic discrimination in employment. This forms the bases for a modern and humanized genomic medicine environment in the country.
Collaboration and Partnerships across Value Chain to Accelerate the Market Entry
Only 15 to 20% of biopharmaceutical companies, such as Roche, Abbott, and Novartis, have meaningful capabilities and presence in the commercial market. For most of the other companies, the development of commercial diagnostics is not a core competency, and they need to rely on diagnostic and biotech and Life sciences companies to successfully launch companion diagnostics. For instance, in the last five years, more than 60 deals have been finalized between biopharmaceutical and diagnostic/Life sciences companies to market companion diagnostics. In the future, the precision medicine market offers a lot more opportunities for mutual benefits for all the players in the value chain.
The genomics segment held a large market share in 2024 due to the growing advancements in sequencing technology. Genomics play a key role in identifying genetic variations associated with disease. Furthermore, the increasing area of applications of genomics, including oncology, neurology, cardiology, and rare genetic diseases, contribute to segmental growth.
The pharmacogenomics segment is expected to grow significantly in the coming years due to the growing adoption of pharmacogenomics testing in clinical practices. Advancements in pharmacogenomics expected to pave the way for drug discovery. Pharmacogenomics predict the efficacy of drugs and helps in understanding the differences in pharmacokinetics and pharmacodynamics using individual’s genetic information.
The therapeutics segment accounted for major market share in 2024 and is projected to register a substantial growth rate during the assessment period. The growth of the segment is attributed to the increasing focus on targeted therapies for specific genetic mutation. Additionally, the rising instances of chronic diseases boost the segment, as chronic diseases required tailored therapeutic approach for effective management of disease.
The oncology segment led the global precision medicine market with significant revenue share in 2024 and is anticipated to grow at a substantial rate during the forecast period. Increasing prevalence of cancer across the globe is likely boost the demand for precision medicine for effective therapeutic approach. Precision medicine helps to examine the patient’s genes and the root cause of the cancer disease. It also helps in designing personalized medicine for the patient to cure them in less time as compared to conventional treatment methods.
The hospitals segment captured a large share of the market in 2024 owing to the high adoption rate of targeted therapeutics among hospitals & clinics. Healthcare providers are increasingly embracing precision medicine due to the rising awareness about the benefits of targeted therapies. Additionally, the easy availability and accessibility of advanced healthcare technologies in hospital settings boost the segment.
By Technology
By Application
By End-Use
By Sequencing Technology
By Product
By Route of Administration
By Drugs
By Regional Outlook
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
September 2023
January 2025
November 2024
April 2025